Biomarker Signatures Correlate With Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-14-0923-t
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Circulating VEGF and eNOS Variations as Predictors of Outcome in Metastatic Colorectal Cancer Patients Receiving Bevacizumab

Scientific Reports
Multidisciplinary
2017English

Anticoagulant Therapy for Venous Thromboembolism Detected by Doppler Ultrasound in Patients With Metastatic Colorectal Cancer Receiving Bevacizumab

OncoTargets and Therapy
OncologyPharmacology
2015English

Utilization of Bevacizumab Among Medicare Patients With Colorectal Cancer Receiving Chemotherapy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

Angiogenesis Genotyping and Clinical Outcome During Regorafenib Treatment in Metastatic Colorectal Cancer Patients

Scientific Reports
Multidisciplinary
2016English

Hypertension and Overall Survival in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Containing Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2011English

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients

Frontiers in Oncology
Cancer ResearchOncology
2019English

Effect and Safety of Bevacizumab-Containing Chemotherapy Treatment in Chinese Patients With Metastatic Colorectal Cancer

OncoTargets and Therapy
OncologyPharmacology
2013English

Reply: Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy